Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22817639 | 0.80 | KDM4E (0.34) | KDM4EALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL22817640 | 0.75 | KDM4E (0.38) | KDM4EALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL19059390 | 0.67 | AHR (0.44) | KDM4EALDH1A1TSHRKMT2AHSD17B10 | |
| SCHEMBL15459460 | 0.64 | HSD17B10 (0.43) | KDM4EALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL9881406 | 0.62 | KDM4E (0.37) | KDM4EALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL20307234 | 0.62 | DYRK1A (0.35) | KDM4E | |
| SCHEMBL21341793 | 0.62 | KDM4E (0.43) | KDM4EALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL12989313 | 0.61 | KDM4E (0.47) | KDM4EPKM | |
| SCHEMBL12989131 | 0.61 | KDM4E (0.47) | KDM4EPKM | |
| SCHEMBL19833112 | 0.61 | ALDH1A1 (0.32) | ALDH1A1MEN1TSHRKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-20200399270-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | EZH1, EZH2, IKZF3 | KDM4E 61/4885ALDH1A1 2385/4885MEN1 266/4885 |
| US-20200399270-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | EZH1, EZH2, IKZF3 | KDM4E 61/4885ALDH1A1 2385/4885MEN1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.